

PATENT APPLICATION ATTORNEY DOCKET 27129/33638A (now 297 5/33638A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 🐉

In re Application of: Ammons et al.)	I hereby certify that this paper is being
)	deposited with the United States Postal
Serial No: 09/416,828)	Service as First Class Mail, postage prepaid
)	in an envelope addressed to: Commissioner μ
Filed: October 12, 1999	·)	for Patents, Washington, D.C. 20231, on
)	this date:
For: "Method of Treating Conditions)	<i>'</i> //'
Associated with Intestinal)	January 9, 2001
Ischemia/Reperfusion)	
Group Art Unit: 1646)	Litten Par Louis
	í	Li-Hsien Rin-Laures, M.D.
Examiner: not assigned)	Registration No. 33,547
<i>3</i>	. ,	1051000001110. 33,37/

RE-TRANSMITTAL OF SEQUENCE LISTING STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

January 9, 2001

Chicago, Illinois

In response to the Office Action and Notice to Comply with sequence listing requirements mailed December 18, 2000, enclosed is a copy of the Sequence Listing Statement filed with the application.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN

Li-Hsien Rin-Laures, M.D. Registration No. 33,547

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300

By:

Ą.

¥.

APPLICANT

plication No.: <u>09416828</u> NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for th following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been sumitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requiremens of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sewence Listing." 5. The computer readable form that has been filed with this application has bein found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(). 6. The paper copy of the "Sequence Listing" is not the same as the computer padable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: See MPEP 2422.05 for transferring the computer readable form of sequence listing from a parent or previously filed application in which a complying computeredable form had been **Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence sting".

An initial or substitute paper copy of the "Sequence Listing", as well as an antidment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are e same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.82 or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please ontact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOR RESPONSE